243 related articles for article (PubMed ID: 32673292)
1. Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.
Yang Y; Neo SY; Chen Z; Cui W; Chen Y; Guo M; Wang Y; Xu H; Kurzay A; Alici E; Holmgren L; Haglund F; Wang K; Lundqvist A
J Clin Invest; 2020 Oct; 130(10):5508-5522. PubMed ID: 32673292
[TBL] [Abstract][Full Text] [Related]
2. NK cells in the tumor microenvironment and thioredoxin activity.
Whiteside TL
J Clin Invest; 2020 Oct; 130(10):5115-5117. PubMed ID: 32925168
[TBL] [Abstract][Full Text] [Related]
3. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
Carrega P; Morandi B; Costa R; Frumento G; Forte G; Altavilla G; Ratto GB; Mingari MC; Moretta L; Ferlazzo G
Cancer; 2008 Feb; 112(4):863-75. PubMed ID: 18203207
[TBL] [Abstract][Full Text] [Related]
5. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress.
Mimura K; Kua LF; Shimasaki N; Shiraishi K; Nakajima S; Siang LK; Shabbir A; So J; Yong WP; Kono K
Cancer Immunol Immunother; 2017 May; 66(5):605-613. PubMed ID: 28224212
[TBL] [Abstract][Full Text] [Related]
7. Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Front Immunol; 2018; 9():3101. PubMed ID: 30774636
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity.
Ni J; Wang X; Stojanovic A; Zhang Q; Wincher M; Bühler L; Arnold A; Correia MP; Winkler M; Koch PS; Sexl V; Höfer T; Cerwenka A
Immunity; 2020 Jun; 52(6):1075-1087.e8. PubMed ID: 32445619
[TBL] [Abstract][Full Text] [Related]
9.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
10. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Blood; 2016 Sep; 128(11):1475-89. PubMed ID: 27465917
[TBL] [Abstract][Full Text] [Related]
11. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
12. Functional and metabolic targeting of natural killer cells to solid tumors.
Wang J; Matosevic S
Cell Oncol (Dordr); 2020 Aug; 43(4):577-600. PubMed ID: 32488848
[TBL] [Abstract][Full Text] [Related]
13. Phenotype and Function of Activated Natural Killer Cells From Patients With Prostate Cancer: Patient-Dependent Responses to Priming and IL-2 Activation.
Hood SP; Foulds GA; Imrie H; Reeder S; McArdle SEB; Khan M; Pockley AG
Front Immunol; 2018; 9():3169. PubMed ID: 30761160
[No Abstract] [Full Text] [Related]
14. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
[TBL] [Abstract][Full Text] [Related]
15. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer.
Hu D; Shen W; Gong C; Fang C; Yao C; Zhu X; Wang L; Zhao C; Zhu S
J Cell Mol Med; 2021 Mar; 25(6):2900-2908. PubMed ID: 33506637
[TBL] [Abstract][Full Text] [Related]
16. Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration.
Yamaguchi R; Perkins G
Cancer Biol Ther; 2018; 19(9):745-754. PubMed ID: 29723108
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients.
Xu B; Chen L; Li J; Zheng X; Shi L; Wu C; Jiang J
Oncotarget; 2016 Nov; 7(46):74904-74916. PubMed ID: 27736796
[TBL] [Abstract][Full Text] [Related]
18. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Neo SY; Yang Y; Record J; Ma R; Chen X; Chen Z; Tobin NP; Blake E; Seitz C; Thomas R; Wagner AK; Andersson J; de Boniface J; Bergh J; Murray S; Alici E; Childs R; Johansson M; Westerberg LS; Haglund F; Hartman J; Lundqvist A
J Clin Invest; 2020 Mar; 130(3):1185-1198. PubMed ID: 31770109
[TBL] [Abstract][Full Text] [Related]
19. High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial.
Holmen Olofsson G; Mikkelsen MK; Ragle AM; Christiansen AB; Olsen AP; Heide-Ottosen L; Horsted CB; Pedersen CMS; Engell-Noerregaard L; Lorentzen T; Persson GF; Vinther A; Nielsen DL; Thor Straten P
BMC Cancer; 2022 Mar; 22(1):246. PubMed ID: 35247994
[TBL] [Abstract][Full Text] [Related]
20. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
